<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03715166</url>
  </required_header>
  <id_info>
    <org_study_id>CL3-95008-001</org_study_id>
    <secondary_id>2017-004419-38</secondary_id>
    <nct_id>NCT03715166</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder</brief_title>
  <official_title>A 6-month Randomised, Double-blind, Placebo Controlled Multicentre Parallel Group Study to Evaluate Efficacy and Safety of Bumetanide 0.5mg Twice a Day Followed by an Open Label Active 6-month Treatment Period With Bumetanide (0.5mg Twice a Day) and a 6 Weeks Discontinuation Period After Treatment Stop.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ADIR, a Servier Group company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and the safety of bumetanide/S95008 in
      the improvement of Autism Spectrum Disorder core symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study (CL3-95008-001) will be performed in children and adolescents from 7 to
      less than 18 years old presenting with ASD. A 6-month double-blind treatment period will be
      performed in which efficacy and safety of bumetanide 0.5mg BID will be assessed versus
      placebo. This double-blind period will be followed by a 6-month open label treatment period
      of bumetanide 0.5mg BID in which long term safety will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 24, 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>6-month, randomized, double-blind, placebo-controlled, parallel groups followed by an open label active 6-month treatment period with bumetanide.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Childhood Autism Rating Scale, Second Edition (CARS2) total raw score</measure>
    <time_frame>Change from baseline to 6 month</time_frame>
    <description>Efficacy criterion The CARS2 is a 15 item rated instrument. The rating values given for the 15 areas are summed to produce a Total score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Social Responsiveness Scale, Second Edition (SRS-2) total raw score</measure>
    <time_frame>Change from baseline to 6 month</time_frame>
    <description>Efficacy criterion 65 items scale measuring symptoms associated with autism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Global Improvement (CGI-I) score</measure>
    <time_frame>At 6 months</time_frame>
    <description>Efficacy criterion Scale which assesses the severity of the illness and the global improvement of the patient under study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vineland Adaptative Behaviour Sales, Second Edition (VABS II) subscores</measure>
    <time_frame>Change from baseline to 6 month</time_frame>
    <description>Efficacy criterion Scale designated to measure adaptative behaviour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and Paediatric Adverse Event Rating Scale (PAERS)</measure>
    <time_frame>On average of 52 weeks</time_frame>
    <description>Safety criterion Inventory report used to identify signs/symptoms experienced by the patient since the study treatment initiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormalities in 12-leads electrocardiogram (ECG) parameters</measure>
    <time_frame>selection visit/Week004/Week008/Week012/Week 026/Week030/Week034/Week038/Week052</time_frame>
    <description>Safety criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal ultrasound</measure>
    <time_frame>selection visit/Week026/Week052</time_frame>
    <description>Safety criterion Assessment of the renal function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Columbia Suicide Severity Rating Scale Children's version (C-SSRS-C)</measure>
    <time_frame>Week000/Week012/Week026/Week038/Week052</time_frame>
    <description>Scale which assesses suicidal ideation and suicidal behaviour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tanner stage</measure>
    <time_frame>Week000/Week026/Week052</time_frame>
    <description>Safety criterion Assessment of Pubertal development</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability and palatability questionnaire</measure>
    <time_frame>Week026</time_frame>
    <description>Acceptability and palatability criterion Assessment of the ease of use to use the dosing device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paediatric Quality of Life Inventory (PedsQL) questionnaire</measure>
    <time_frame>Week000/Week004/Week012/Week026/Week030/Week038/Week052</time_frame>
    <description>Quality of Life criterion Assessment of parent/legal representative perception of patient health related quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Autism Spectrum Disorder (ASD)</condition>
  <arm_group>
    <arm_group_label>Bumetanide/S95008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bumetanide Oral Solution</intervention_name>
    <description>Oral Solution dosed at 0.5mg/mL Taken twice daily</description>
    <arm_group_label>Bumetanide/S95008</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Solution Taken twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients from 7 to less than 18 years

          -  Out patients

          -  Primary diagnosis of ASD as per Diagnostic and Statistical Manual of Mental Disorders
             - Fifth Edition (DSM-5) criteria

          -  Criteria met for ASD on Autism Diagnostic Observation Schedule (ADOS-2) and Autism
             Diagnosis Interview Revised (ADI-R)

          -  CGI (Clinical Global Impression) - Severity rating Score ≥ 4

          -  Childhood Autism Rating Scale second edition (CARS2-ST or HF) total raw score ≥ 34

          -  Social responsiveness Scale second edition total score (SRS-2 T-Score) ≥ 66

          -  Absence of known monogenic syndrome (Fragile X, Rett syndrome ...)

          -  Absence of any clinically significant abnormality likely to interfere with the conduct
             of the study according to the judgment of the investigator

        Exclusion Criteria:

          -  Patients not able to follow the study assessments defined by the protocol, with the
             exception of self-rating questionnaires which will be assessed by parent/legal
             representative/caregiver for those patients unable to complete them

          -  Patients having a high suicidal risk according to the investigator judgement

          -  Chronic renal dysfunction

          -  Chronic cardiac dysfunction

          -  Patient with unstable psychotherapy, behavioural, cognitive or cognitive-behavioural
             therapy

          -  Severe electrolyte imbalance that is likely to interfere with the study conduct or
             evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Trial Tech em Pesquisas com Medicamentos Ltda</name>
      <address>
        <city>Curitiba</city>
        <zip>80240-280</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário Walter Cantídio - Universidade Federal do Ceará</name>
      <address>
        <city>Fortaleza</city>
        <zip>60430-370</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital São Vicente de Paulo</name>
      <address>
        <city>Passo Fundo</city>
        <zip>99010-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de São Paulo, Escola Paulista de Medicina</name>
      <address>
        <city>São Paulo</city>
        <zip>04017-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina da Universidade de São Paulo - Departamento de Psiquiatria</name>
      <address>
        <city>São Paulo</city>
        <zip>054030-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSC CHU-LENVAL Centre ressource autisme</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>6200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg Service de Psychiatrie de l'Enfant et de l'Adolescent</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace-Champagne-Ardenne-Lorraine</state>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique de Lyon</name>
      <address>
        <city>Bron</city>
        <state>Auvergne Rhone Alpes</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Le Vinatier CRA Rhône-Alpes, Bat 211</name>
      <address>
        <city>Bron</city>
        <state>Auvergne-Rhône-Alpes</state>
        <zip>69678</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré Service de Psychiatrie de l'enfant et de l'adolescent</name>
      <address>
        <city>Paris</city>
        <state>Il De France</state>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <state>Normandie</state>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Rouvray Centre de Ressources pour l'Autisme</name>
      <address>
        <city>Sotteville-lès-Rouen</city>
        <state>Normandie</state>
        <zip>76301</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital des Enfants-Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <state>Nouvelle Aquitaine</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Charles Perrens CRA Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <state>Nouvelle-Aquitaine</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Zentrum für Psychische Erkrankungen, Klinik für Psychiatrie, Psychotherapie und Psychosomatik im Kindes- und Jugendalter</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters am Zentralinstitut für Seelische Gesundheit</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der TU Dresden, Klinik und Poliklinik für Kinder- und Jugendpsychiatrie und</name>
      <address>
        <city>Dresden</city>
        <state>Saxony (Sachsen)</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vadaskert Korhaz es Szakambulancia</name>
      <address>
        <city>Budapest</city>
        <zip>1021</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servus Salvus Fft.</name>
      <address>
        <city>Budapest</city>
        <zip>1026</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kozponti Korhaz Gyermek es ifjusagpszichiatriai osztaly</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudományegyetem Szent-Gyorgy Albert Klinikai Kozpont Gyermekgyógyászati Klinika Gyermek es Ifjusagpszichiátriai o</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Semplice di Psichiatria Infantile Policlinico Universitario di Napoli - Università Federico II</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro Riabilitazione/Psicopatologia dell'età evolutiva Istituto Scientifico Medea - Bosisio Parini</name>
      <address>
        <city>Bosisio Parini</city>
        <state>Lombardia</state>
        <zip>23842</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Neuropsichiatria Infantile Fondazione Istituto Neurologico Nazionale Casimiro Mondino Istituto di Ricovero e Cura a Carattere Scientifico</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica di Neuropsichiatria dell'Infanzia e dell'Adolescenza Ospedale Pediatrico-Microcitemico</name>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Programma Interdipartimentale &quot;Autismo 0-90&quot; A.O.U. Policlinico &quot;Gaetano Martino&quot;</name>
      <address>
        <city>Messina</city>
        <state>Sicilia</state>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Psichiatria dello Sviluppo IRCCS Fondazione Stella Maris</name>
      <address>
        <city>Calambrone</city>
        <state>Toscana</state>
        <zip>56128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Neuropsichiatria Infantile Azienda Ospedaliera Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <state>Toscana</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accare Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NAVICULA Centrum Diagnozy i Terapii Autyzmu w Łodzi</name>
      <address>
        <city>Lodz</city>
        <state>Wojewodztwo Lodzkie</state>
        <zip>91-129</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Dziecięcy Szpital Kliniczny w Warszawie Oddział Kliniczny Psychiatrii Wieku Rozwojowego</name>
      <address>
        <city>Warsaw</city>
        <state>Wojewodztwo Mazowieckie</state>
        <zip>02-091</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zakład Opieki Zdrowotnej Gdańskie Centrum Zdrowia Sp. z o.o.</name>
      <address>
        <city>Gdansk</city>
        <state>Wojewodztwo Pomorskie</state>
        <zip>80-542</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badań Klinicznych PI-House sp. z o.o</name>
      <address>
        <city>Gdansk</city>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacja SYNAPSIS ul.</name>
      <address>
        <city>Warszawa</city>
        <zip>02-085</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar e Universitario de Coimbra Hospital Pediatrico</name>
      <address>
        <city>Coimbra</city>
        <zip>300-062</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospita Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinica Guipuzcoa</name>
      <address>
        <city>San Sebastian</city>
        <state>Guipuzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Usm Infantil Benalua</name>
      <address>
        <city>Alicante</city>
        <zip>03007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Niño Jesus</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forward Thinking Birmingham_Birmingham Women's and Children's NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ReCognition Health</name>
      <address>
        <city>London</city>
        <zip>W1G 9JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Winnicott Centre</name>
      <address>
        <city>Manchester</city>
        <zip>M13 0JE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <link>
    <url>https://clinicaltrials.servier.com/</url>
    <description>Find Results on Servier Clinical Trial Data website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 12, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bumetanide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.
They can ask for all interventional clinical studies:
submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After Marketing Authorisation in EEA or US if the study is used for the approval.</ipd_time_frame>
    <ipd_access_criteria>Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.</ipd_access_criteria>
    <ipd_url>http://clinicaltrials.servier.com/</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>study-level clinical trial data</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

